Biocon Biologics, one of India's leading biologic drug manufacturers, announced on Friday the results of a Phase-3 study on a ...
Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...
Some patients with psoriasis may have a super response to guselkumab, but questions remain regarding the generalizability of treatment strategies.
Discover a study that concludes that the DermSat-7 is a valid and reliable instrument for measuring treatment satisfaction in ...
Patients treated with ESK-001 for moderate to severe plaque psoriasis experienced positive clinical responses through a year, ...
In a cohort of more than 11,000 patients from the U.K. and Ireland, a comparable proportion of new adalimumab users achieved ...
Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...
Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm Nearly half of patients with moderate-to-severe ...
Scalp psoriasis can cause crusty patches or scales on the surface of the head. Find details about medicated shampoos, ...
SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oral small-molecule biosynthetic ...
Topline results from Phase 3 ICONIC-ADVANCE 1&2�studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO ...
Tildrakizumab showed early and sustained effectiveness and quality of life (QOL) improvements in patients with moderate to ...